Results 171 to 180 of about 1,438,958 (298)

Proteogenomic Characterization Reveals Subtype‐Specific Therapeutic Potential for HER2‐Low Breast Cancer

open access: yesAdvanced Science, EarlyView.
Multiomic profiling of HER2‐low breast cancer identifies three proteomic subtypes with distinct therapeutic strategies: endocrine, antiangiogenic, and anti‐HER2 therapies. Genomic and lactate modification landscapes are detailed, providing insights for precise management.
Shouping Xu   +20 more
wiley   +1 more source

Dual Targeting of Mutant p53 and SNRPD2 via Engineered Exosomes Modulates Alternative Splicing to Suppress Ovarian Cancer

open access: yesAdvanced Science, EarlyView.
Mutant p53 drives oncogenic splicing to promote the progression of ovarian cancer by partnering with the spliceosome factor SNRPD2. Therefore, it is engineered iRGD‐exosomes to co‐deliver siRNAs against both targets. This approach restored tumor‐suppressive mRNA isoforms, effectively enhanced sensitivity to cisplatin, and ultimately blocked tumor ...
Wei Zhao   +14 more
wiley   +1 more source

An unusual case of sodium citrate-dependent artifactual platelet count. [PDF]

open access: yesInterv Med Appl Sci, 2020
Dima F   +4 more
europepmc   +1 more source

Astrocytic PCBP1 Suppresses Ferroptosis to Restore Glutamatergic Homeostasis and Mitigate Stress‐Induced Depression in Male Mice

open access: yesAdvanced Science, EarlyView.
This study demonstrates that polyC‐RNA‐binding protein 1 (PCBP1) in ventral hippocampal astrocytes modulates depressive‐like behaviors by regulating glutathione peroxidase 4‐mediated ferroptosis and synaptic glutamatergic transmission. PCBP1 overexpression intervention in the chronic unpredictable mild stress model rescues behavioral deficits ...
Jinyu Zhang   +15 more
wiley   +1 more source

Cancer Stem Cells Shift Metabolite Acetyl‐Coenzyme A to Abrogate the Differentiation of CD103+ T Cells

open access: yesAdvanced Science, EarlyView.
Lei et al. demonstrate that cancer stem cells (CSCs) play a pivotal role in impairing the differentiation of CD103+ T cells in patients with non‐small‐cell lung cancer. The key mechanism involves CSC‐derived acetyl‐CoA, which disrupts CD103+ T cell differentiation by sequentially inducing acetylation and ubiquitination of the Blimp‐1 protein. Targeting
Jiaxin Lei   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy